

PHYSICIAN
DOCTOR, TEST
 1234 MAIN STREET
 ANYTOWN, USA 12345

 Acct #: (XXXXX-X)
 Tel:(555) 555-5555

PATIENT
PATIENT, TEST
 DOB:11/01/1950 Age:69 Y Sex:M
 Address:
 Tel:

SAMPLE
 Specimen ID: XXXXXXXX
 Date Of Report: 01/18/2020
 Time Of Report:
 Date Collected: 01/16/2020
 Time Collected:
 Date Received: 01/16/2020
 Time Received:
 North America Eastern Time

CLINICAL REPORT

Fax To:

CLINICAL ABNORMALITIES SUMMARY: (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.)

4K SCORE **63**
 PSA Total **4.12 H**

NON FASTING

 Note: The 4Kscore test has been processed. This test was on hold pending complete documentation.

PROSTATE CANCER RISK EVALUATION

Test	Result	Abnormal	Reference	Units	Rpt Date	Prior Result	Date
Prior Biopsy Status: NO PRIOR BIOPSY							
Digital Rectal Exam (DRE): NODULE							

4K SCORE **63** % 01/18/20
 Evaluation: ELEVATED RISK

This test was developed and its performance characteristics were determined by BioReference Laboratories. It has not been cleared by the U.S.Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test.

NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

NOTE: Biotin supplementation (>5 mg/day) may cause interference with assays that are components of the 4Kscore Test, and may impact the 4Kscore result.

MISCELLANEOUS

Test	Result	Abnormal	Reference	Units	Rpt Date	Prior Result	Date
PSA Total		4.12 H	<4.00	ng/mL	01/18/20		

NOTE: NCCN Guidelines(1.2017)recommend repeat testing every 2-4 years if PSA is <1 ng/mL and every 1-2 years if PSA is 1-3 ng/mL in men aged 45 to 75 years. A PSA value of 1.00 ng/mL selects for the upper range of PSA values. Men who have a PSA above the median for their age group are at a higher risk for prostate cancer and for the aggressive form of the disease. The higher above the median, the greater the risk.

NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be based solely upon values obtained from serial PSA values obtained on the

PHYSICIAN
DOCTOR, TEST
 1234 MAIN STREET
 ANYTOWN, USA 12345

 Acct #: (XXXXX-X)
 Tel:(555) 555-5555

PATIENT
PATIENT, TEST
 DOB:11/01/1950 Age:69 Y Sex:M
 Address:
 Tel:

SAMPLE
 Specimen ID: XXXXXXXXX
 Date Of Report: 01/18/2020
 Time Of Report:
 Date Collected: 01/16/2020
 Time Collected:
 Date Received: 01/16/2020
 Time Received:
 North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Rpt Date	Prior Result	Date																				
patient. NOTE: Values obtained with different assay methods or kits cannot be used interchangeably. NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics) NOTE: Biotin supplementation (>5mg/day) may cause interference with this assay.																											
PSA, FREE	0.40		Not Estab.	ng/mL	01/18/20																						
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably. ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics). NOTE: Biotin supplementation (>5mg/day) may cause interference with this assay.																											
% FREE PSA	10		See Below	%	01/18/20																						
FREE PSA RISK ASSESSMENT The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below: PROBABILITY OF CANCER* <table border="1"> <thead> <tr> <th>%free PSA</th> <th>(50-59 yrs)</th> <th>(60-69 yrs)</th> <th>(>or=70 yrs)</th> </tr> </thead> <tbody> <tr> <td><or=10</td> <td>49.2%</td> <td>57.5%</td> <td>64.5%</td> </tr> <tr> <td>11-18</td> <td>26.9%</td> <td>33.9%</td> <td>40.8%</td> </tr> <tr> <td>19-25</td> <td>18.3%</td> <td>23.9%</td> <td>29.7%</td> </tr> <tr> <td>>25</td> <td>9.1%</td> <td>12.2%</td> <td>15.8%</td> </tr> </tbody> </table> *probability of finding prostate cancer by needle biopsy NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E602 immunoassay system.(8/2015;V8.0)								%free PSA	(50-59 yrs)	(60-69 yrs)	(>or=70 yrs)	<or=10	49.2%	57.5%	64.5%	11-18	26.9%	33.9%	40.8%	19-25	18.3%	23.9%	29.7%	>25	9.1%	12.2%	15.8%
%free PSA	(50-59 yrs)	(60-69 yrs)	(>or=70 yrs)																								
<or=10	49.2%	57.5%	64.5%																								
11-18	26.9%	33.9%	40.8%																								
19-25	18.3%	23.9%	29.7%																								
>25	9.1%	12.2%	15.8%																								

Final Report